Literature DB >> 16430202

TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro.

Cécile L Tremblay, Françoise Giguel, Ting-Chao Chou, Huajin Dong, Katsunori Takashima, Martin S Hirsch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16430202

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


× No keyword cloud information.
  5 in total

1.  Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

Authors:  Masanori Baba; Hiroshi Miyake; Xin Wang; Mika Okamoto; Katsunori Takashima
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

3.  The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates.

Authors:  Nina H Lin; Daniel M Negusse; Rameen Beroukhim; Francoise Giguel; Shahin Lockman; Myron Essex; Daniel R Kuritzkes
Journal:  J Virol Methods       Date:  2010-06-25       Impact factor: 2.014

4.  Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Authors:  Jose D Murga; Michael Franti; Daniel C Pevear; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 5.  Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review.

Authors:  Peter Gál; Petra Kravcuková; Michal Mokrý; Darina Kluchová
Journal:  Cell Mol Neurobiol       Date:  2009-04-11       Impact factor: 5.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.